Pernix Therapeutics Holdings Inc. (PTX) 6.79 $PTX
Nasdaq stocks posting largest percentage decreases
AP - Tue Jul 29, 12:30PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Pernix Therapeutics to Report Second Quarter 2014 Financial Results on August 11, 2014
Business Wire - Fri Jul 25, 8:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its second quarter 2014 financial results before the U.S. stock market opens on Monday, August 11, 2014 and has scheduled a conference call at 10:00 a.m. EDT that day to discuss the financial results.
Gyrotron Technology Inc. Elects Jan H. Loeb to Its Board of Directors
Marketwire - Tue Jul 22, 2:11PM CDT
Gyrotron Technology Inc. (PINKSHEETS: GYTI), a developer of innovative industrial technologies, announced today that Mr. Jan H. Loeb has been elected to its Board of Directors.
Commit To Purchase Pernix Therapeutics Holdings At $7.50, Earn 23.9% Annualized Using Options
StockOptionsChannel.com - Fri Jul 11, 11:21AM CDT
Investors considering a purchase of Pernix Therapeutics Holdings, Inc. stock, but cautious about paying the going market price of $8.77/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Pernix Therapeutics hires Sanjay Patel as CFO
M2 - Tue Jun 24, 6:33AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NASDAQ MKT
TX) disclosed on Monday that it has appointed Sanjay Patel as its chief financial officer.
Pernix Therapeutics Appoints Chief Financial Officer
Business Wire - Mon Jun 23, 10:38AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced the appointment of Sanjay Patel as Chief Financial Officer.
Agreements, Orphan Drug Designations, and Management Changes - Analyst Notes on Medtronic, DARA BioSciences, Sequenom, AcelRx and Pernix
PR Newswire - Thu Jun 19, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Medtronic, Inc. (NYSE: MDT), DARA BioSciences, Inc (NASDAQ: DARA), Sequenom Inc. (NASDAQ: SQNM), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) and Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3874-100free.
Pharmaceuticals Stocks Technical Momentum -- Research on Jazz Pharma, Omeros, Pernix Therapeutics Holdings, and Salix Pharma
PR Newswire - Mon Jun 16, 6:10AM CDT
On Friday, June 13, 2014, the NASDAQ Composite ended at 4,310.65, up 0.30%, the Dow Jones Industrial Average finished the day 0.25% higher at 16,775.74, and the S&P 500 closed at 1,936.16, up 0.31%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 688.44, down 0.02%, while the index has advanced 2.46% in the last one month. Investor-Edge has initiated coverage on the following equities: Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), Omeros Corp. (NASDAQ: OMER), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX) and Salix Pharmaceuticals Ltd (NASDAQ: SLXP). Free technical research on JAZZ, OMER, PTX and SLXP can be downloaded upon signing up at:
GSK Keen to Keep Some Emerging Markets Drugs
at The Street - Fri May 30, 10:35AM CDT
Blackstone, KKR and Advent are among the recipients of sales information for the brands on the block.
Why Pernix Theraputics Holdings Inc. Shares Popped Today
Alex Planes, The Motley Fool - Motley Fool - Tue May 27, 5:46PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Pernix Theraputics Holdings Inc. closed...
Pernix Therapeutics to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 8:34AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company" (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced that Pernix CEO Doug Drysdale is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 12:50 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector.
Pernix expects USD6.2m in net proceeds and annual cost savings from Pernix Manufacturing LLC's sale
M2 - Wed Apr 02, 5:28AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NASDAQ MKT TX) said on Tuesday that it has entered into a definitive agreement to sell its Houston, TX-based manufacturing operations, Pernix Manufacturing LLC (PML).
Pernix Agrees to Divest Manufacturing Facility
Business Wire - Tue Apr 01, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company" (NASDAQ MKT TX), a specialty pharmaceutical company, today announced that it has signed a definitive agreement to divest its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC ("PML" to Woodfield Pharmaceutical LLC ("Woodfield" .
Health Care Stocks on our Radar -- Research on Novo Nordisk, Tianyin Pharma, Pernix Therapeutics Holdings, and Oculus Innovative Sciences
PR Newswire - Wed Mar 26, 12:10PM CDT
On Tuesday, March 25, 2014, the NASDAQ Composite finished at 4,234.27, up 0.19%. The Dow Jones Industrial Average closed the session at 16,367.88, up 0.56% and the S&P 500 ended the day at 1,865.62, higher by 0.44%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, and the same has gained 5.27% in the previous three months. Investor-Edge has initiated coverage on the following equities: Novo Nordisk A/S (NYSE: NVO), Tianyin Pharmaceutical Co. Inc. (NYSE MKT: TPI), Pernix Therapeutics Holdings (NASDAQ: PTX) and Oculus Innovative Sciences Inc. (NASDAQ: OCLS). Free technical research on NVO, TPI, PTX and OCLS can be downloaded upon signing up at:
Commit To Purchase Pernix Therapeutics Holdings At $5, Earn 24.1% Annualized Using Options
StockOptionsChannel.com - Tue Mar 25, 11:19AM CDT
Investors considering a purchase of Pernix Therapeutics Holdings, Inc. stock, but cautious about paying the going market price of $5.66/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Pernix Therapeutics Appoints Senior Vice President of Sales and Marketing
Business Wire - Tue Mar 18, 9:35AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company" (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced the appointment of Rick Shalaby as Senior Vice President of Sales and Marketing effective March 17, 2014.
Pernix Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Mon Mar 17, 7:01AM CDT
--Quarter over Quarter Revenue Increased by 31.5% to $24 Million
Pernix Therapeutics Appoints John Sedor to Its Board of Directors
Business Wire - Thu Mar 13, 11:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of John Sedor as a non-executive Director and Chairman of the Compensation Committee of its Board of Directors. Mr. Sedor has more than 30 years of proven leadership in the global pharmaceutical, biopharmaceutical, consumer product and generic drug industries. John is recognized for his entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise. Prior to his current role as President and CEO at Rodes Inc., John most recently served as President, CEO and Director of Cangene Corporation, one of the world's leading biopharmaceutical companies in the development, manufacture and commercialization of therapies targeting infectious disease, hematology/oncology and transplantation. Under his guidance, Cangene was acquired by Emergent BioSolutions in February 2014. Prior to joining Cangene, he served as President, CEO and Director of CPEX Pharmaceuticals, Inc., a specialty drug delivery pharmaceutical company, and managed its spin-off from Bentley Pharmaceuticals, Inc. Prior to that, he was President of Bentley, which expanded its nanotechnology programs and added more than 20 new product approvals in the European market under his leadership. In 1996, John created Centeon LLC to develop and commercialize plasma protein biotherapeutics. Other previous roles include President of Sandoz Inc. (Novartis), and various senior positions at Verion, Rorer Pharmaceutical Co., Revlon Health Care Group and Armour Pharmaceutical Company.
Pernix Therapeutics appoints Terence Novak as COO
M2 - Tue Mar 11, 6:24AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NasdaqGM TX) disclosed on Monday that Terence Novak has been elected as its chief operating officer.
Nasdaq stocks posting largest percentage decreases
AP - Tue Jul 29, 12:30PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Pernix Therapeutics to Report Second Quarter 2014 Financial Results on August 11, 2014
Business Wire - Fri Jul 25, 8:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its second quarter 2014 financial results before the U.S. stock market opens on Monday, August 11, 2014 and has scheduled a conference call at 10:00 a.m. EDT that day to discuss the financial results.
Gyrotron Technology Inc. Elects Jan H. Loeb to Its Board of Directors
Marketwire - Tue Jul 22, 2:11PM CDT
Gyrotron Technology Inc. (PINKSHEETS: GYTI), a developer of innovative industrial technologies, announced today that Mr. Jan H. Loeb has been elected to its Board of Directors.
Commit To Purchase Pernix Therapeutics Holdings At $7.50, Earn 23.9% Annualized Using Options
StockOptionsChannel.com - Fri Jul 11, 11:21AM CDT
Investors considering a purchase of Pernix Therapeutics Holdings, Inc. stock, but cautious about paying the going market price of $8.77/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Pernix Therapeutics hires Sanjay Patel as CFO
M2 - Tue Jun 24, 6:33AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NASDAQ MKT
TX) disclosed on Monday that it has appointed Sanjay Patel as its chief financial officer. Pernix Therapeutics Appoints Chief Financial Officer
Business Wire - Mon Jun 23, 10:38AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced the appointment of Sanjay Patel as Chief Financial Officer. Agreements, Orphan Drug Designations, and Management Changes - Analyst Notes on Medtronic, DARA BioSciences, Sequenom, AcelRx and Pernix
PR Newswire - Thu Jun 19, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Medtronic, Inc. (NYSE: MDT), DARA BioSciences, Inc (NASDAQ: DARA), Sequenom Inc. (NASDAQ: SQNM), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) and Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3874-100free.
Pharmaceuticals Stocks Technical Momentum -- Research on Jazz Pharma, Omeros, Pernix Therapeutics Holdings, and Salix Pharma
PR Newswire - Mon Jun 16, 6:10AM CDT
On Friday, June 13, 2014, the NASDAQ Composite ended at 4,310.65, up 0.30%, the Dow Jones Industrial Average finished the day 0.25% higher at 16,775.74, and the S&P 500 closed at 1,936.16, up 0.31%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 688.44, down 0.02%, while the index has advanced 2.46% in the last one month. Investor-Edge has initiated coverage on the following equities: Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), Omeros Corp. (NASDAQ: OMER), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX) and Salix Pharmaceuticals Ltd (NASDAQ: SLXP). Free technical research on JAZZ, OMER, PTX and SLXP can be downloaded upon signing up at:
GSK Keen to Keep Some Emerging Markets Drugs
at The Street - Fri May 30, 10:35AM CDT
Blackstone, KKR and Advent are among the recipients of sales information for the brands on the block.
Why Pernix Theraputics Holdings Inc. Shares Popped Today
Alex Planes, The Motley Fool - Motley Fool - Tue May 27, 5:46PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Pernix Theraputics Holdings Inc. closed...
Pernix Therapeutics to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 8:34AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced that Pernix CEO Doug Drysdale is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 12:50 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector. Pernix expects USD6.2m in net proceeds and annual cost savings from Pernix Manufacturing LLC's sale
M2 - Wed Apr 02, 5:28AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NASDAQ MKT
TX) said on Tuesday that it has entered into a definitive agreement to sell its Houston, TX-based manufacturing operations, Pernix Manufacturing LLC (PML). Pernix Agrees to Divest Manufacturing Facility
Business Wire - Tue Apr 01, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT TX), a specialty pharmaceutical company, today announced that it has signed a definitive agreement to divest its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC ("PML" to Woodfield Pharmaceutical LLC ("Woodfield" . Health Care Stocks on our Radar -- Research on Novo Nordisk, Tianyin Pharma, Pernix Therapeutics Holdings, and Oculus Innovative Sciences
PR Newswire - Wed Mar 26, 12:10PM CDT
On Tuesday, March 25, 2014, the NASDAQ Composite finished at 4,234.27, up 0.19%. The Dow Jones Industrial Average closed the session at 16,367.88, up 0.56% and the S&P 500 ended the day at 1,865.62, higher by 0.44%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, and the same has gained 5.27% in the previous three months. Investor-Edge has initiated coverage on the following equities: Novo Nordisk A/S (NYSE: NVO), Tianyin Pharmaceutical Co. Inc. (NYSE MKT: TPI), Pernix Therapeutics Holdings (NASDAQ: PTX) and Oculus Innovative Sciences Inc. (NASDAQ: OCLS). Free technical research on NVO, TPI, PTX and OCLS can be downloaded upon signing up at:
Commit To Purchase Pernix Therapeutics Holdings At $5, Earn 24.1% Annualized Using Options
StockOptionsChannel.com - Tue Mar 25, 11:19AM CDT
Investors considering a purchase of Pernix Therapeutics Holdings, Inc. stock, but cautious about paying the going market price of $5.66/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Pernix Therapeutics Appoints Senior Vice President of Sales and Marketing
Business Wire - Tue Mar 18, 9:35AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced the appointment of Rick Shalaby as Senior Vice President of Sales and Marketing effective March 17, 2014. Pernix Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Mon Mar 17, 7:01AM CDT
--Quarter over Quarter Revenue Increased by 31.5% to $24 Million
Pernix Therapeutics Appoints John Sedor to Its Board of Directors
Business Wire - Thu Mar 13, 11:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of John Sedor as a non-executive Director and Chairman of the Compensation Committee of its Board of Directors. Mr. Sedor has more than 30 years of proven leadership in the global pharmaceutical, biopharmaceutical, consumer product and generic drug industries. John is recognized for his entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise. Prior to his current role as President and CEO at Rodes Inc., John most recently served as President, CEO and Director of Cangene Corporation, one of the world's leading biopharmaceutical companies in the development, manufacture and commercialization of therapies targeting infectious disease, hematology/oncology and transplantation. Under his guidance, Cangene was acquired by Emergent BioSolutions in February 2014. Prior to joining Cangene, he served as President, CEO and Director of CPEX Pharmaceuticals, Inc., a specialty drug delivery pharmaceutical company, and managed its spin-off from Bentley Pharmaceuticals, Inc. Prior to that, he was President of Bentley, which expanded its nanotechnology programs and added more than 20 new product approvals in the European market under his leadership. In 1996, John created Centeon LLC to develop and commercialize plasma protein biotherapeutics. Other previous roles include President of Sandoz Inc. (Novartis), and various senior positions at Verion, Rorer Pharmaceutical Co., Revlon Health Care Group and Armour Pharmaceutical Company.
Pernix Therapeutics appoints Terence Novak as COO
M2 - Tue Mar 11, 6:24AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NasdaqGM
TX) disclosed on Monday that Terence Novak has been elected as its chief operating officer. 
